The company had expenses of RON265.7 million, up 36% compared to the first nine months of 2013, Zentiva said in its earnings report Friday.
The pharmaceutical company’s turnover stood at RON311.3 million in the first nine months, up 31%from the RON237.7 million it posted in the same period last year.
Zentiva estimates its turnover will grow 8.4% this year, to RON348 million, and sees its profit rising 18.6%, to RON47.8 million.
The company’s production unit in Bucharest has planned to invest EUR7 million this year in production equipment and facilities.
According to the latest available data, French group Sanofi-Aventis owns 81.6% of Zentiva Romania’s shares.
On the Bucharest Stock Exchange Friday, Zentiva stock was trading at RON1.345 a share, up 0.37%.